Factor VIII (fVIII) 1 is the large (M r Ϸ 300,000) plasma glycoprotein that is missing or deficient in hemophilia A. It contains a sequence of domains designated NH 2 -A1-A2-B-A3-C1-C2-COOH (1) . Inhibitory antibodies (inhibitors) to fVIII can arise as alloantibodies in patients with hemophilia A transfused with fVIII or as autoantibodies in non-hemophiliacs (2) . They present a serious challenge in the management of bleeding disorders. Most fVIII inhibitor plasmas contain antibodies that bind to epitopes located in the A2, C2, and/or A3-C1 domains of fVIII (3) (4) (5) (6) (7) (8) . Porcine fVIII usually exhibits limited cross-reactivity with anti-human fVIII antibodies (9 -11) , which forms the basis for porcine fVIII therapy of fVIII inhibitor patients (10, (12) (13) (14) (15) (16) .
We have used recombinant hybrid human/porcine fVIII molecules to map a major inhibitor epitope determinant to a 25-residue segment bounded by residues Arg 484 -Ile 508 in the A2 domain (17) . In this region, there are nine amino acid differences between human and porcine fVIII (18) . In the present study, we constructed human fVIII cDNAs that encode single alanine substitutions at positions where the human and porcine fVIII sequences differ to identify specific amino acid residues that contribute to the A2 inhibitor epitope. These constructs were stably expressed as active fVIII molecules in mammalian cells, and their inhibition by mAb413 (a model murine monoclonal A2 inhibitor) and by a panel of A2-specific patient antibodies was measured.
EXPERIMENTAL PROCEDURES
Materials-Citrated hemophilia A plasma and normal pooled human plasmas were purchased from George King Biomedical, Inc. (Overland Park, KS). Immunoaffinity-purified, albumin-free recombinant human fVIII was a generous gift from Baxter Biotech. mAb413 IgG was prepared as described previously (6) . Heparin-Sepharose was purchased from Sigma. DNA modification enzymes were obtained from New England Biolabs (Beverly, MA) or Promega Corp. (Madison, WI). Bluescript II K/S Ϫ phagemid was purchased from Stratagene (La Jolla, CA). Oligonucleotide PCR primers, fetal bovine serum, AIM-V expression medium, geneticin, penicillin, and streptomycin were purchased from Life Technologies, Inc. Deep Vent DNA polymerase was used for all PCR reactions and was purchased from New England Biolabs. cDNAs corresponding to human B-domainless (B Ϫ ) fVIII (fVIII des741-1648 ), and hybrid human/porcine B Ϫ fVIII molecules HP9, HP12, and HP13 were prepared as described previously (17) . Ϫ by splicing-by-overlap extension (SOE) mutagenesis (20) using conditions as described previously (17) . SOE mutagenesis consists of two rounds of PCR using outer primer pairs a (sense) and d (antisense), that are common to all reactions, and inner primer pairs b (sense) and c (antisense), that define the splice site. The a and d primers were 5Ј-GGC ATG GAA GCT TAT GTC AAA G-3Ј and 5Ј-CCT CTT TGG TCT ACA GAT TCT TTG-3Ј, respectively. The 5Ј residues of a and d correspond to nucleotides 1012 and 1722, respectively, in human fVIII. To * This work was supported by National Institutes of Health Grants R01-HL46215 (to P. L.) and P50-HL44336 (to D. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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introduce the MluI site, b and c primers were 5Ј-GAA ACC TTT AAG ACG CGT GAA GCT A-3Ј and 5Ј-TAG CTT CAC GCG TCT TAA AGG TTT C-3Ј, respectively. To introduce the SacII site, b and c primers were 5Ј-AAA TCA GAT CCG CGG TGC CT-3Ј and 5Ј-AGG CAC CGC GGA TCT GAT TT-3Ј, respectively. Expression of Recombinant Proteins-Human B Ϫ fVIII and B Ϫ fVIII mutant cDNAs in the expression vector ReNeo were stably incorporated into baby hamster kidney cell DNA using geneticin selection, expressed in 10% fetal bovine serum, concentrated and partially purified by heparin-Sepharose chromatography as described previously (17, 18) . Two of the constructs, fVIII Tyr 487 3 Ala and fVIII Arg 489 3 Ala, also were expressed in AIM-V, a serum-free medium. AIM-V was substituted for 10% fetal bovine serum after baby hamster kidney cells stably transfected fVIII Tyr 487 3 Ala or fVIII Arg 489 3 Ala had reached confluence. Medium was harvested every 12-24 h for 5 days and stored at 4°C prior to heparin-Sepharose chromatography.
Assays-fVIII antigen levels were measured by enzyme-linked immunosorbent assay (ELISA) using murine monoclonal anti-fVIII light chain antibodies for capture and detection as described previously (18) . Recombinant human fVIII was used to construct the standard curve. fVIII activity was measured in a one-stage clotting assay as described previously (21) . The coefficients of variation of replicate determinations in the clotting assay and ELISA were used to estimate the uncertainty in the specific activity by propagation of error analysis. The specific activity of human B Ϫ determined by this method is 3600 Ϯ 210 units/mg (mean Ϯ S.D.). fVIII inhibitor titers against human B Ϫ fVIII and fVIII mutants were measured using the Bethesda assay (22) as described previously (18) with the following modification to the analysis. Percent residual fVIII activity was plotted as a function of dilution of inhibitor sample, and the data were fitted by nonlinear, least-squares analysis using the Marquardt algorithm (23) to the empirical equation below, where I is the concentration of inhibitor plasma (i.e. the reciprocal of the dilution) and IC 50 , the fitted parameter, is the concentration of inhibitor plasma that produces 50% inhibition (Equation 1).
The reciprocal of the IC 50 is the Bethesda titer reported as units/ml for patient plasmas and units/mg for mAb413 IgG. The coefficient of variation of the IC 50 resulting from the least-squares fit was multiplied by the Bethesda titer to provide an estimate of the S.D. of the Bethesda titer. Data are presented in the figures as mean Ϯ 1 S.D.
Patient Plasmas-A2-specific patient plasmas CHA, JM, NS, and RC were identified from a large panel of inhibitor plasmas based on the observation that their fVIII inhibitory activity is greater than 90% neutralized by recombinant A2 domain and is not detectably neutralized by fVIII light chain, which contains the A3, C1, and C2 domains (7, 24) . Plasma from patient WD is 56% neutralized by recombinant A2 domain, but also contains inhibitory antibodies to the light chain and to an epitope that has been mapped to Glu 341 -Asp 362 in the acidic region of the A1 domain (24) . Thus, most of its activity is A2-directed.
RESULTS
Characterization of fVIII Alanine Mutants-Nine B-domainless fVIII A2 alanine mutants corresponding to the nine sites where human and porcine sequences differ in the region bounded by Arg 484 -Ile 508 were prepared as described under "Experimental Procedures" (Fig. 1) . The mutant cDNAs were stably expressed in baby hamster kidney cells, and mutant proteins were partially purified from conditioned medium. Coagulant activity was measured in a one-stage clotting assay, and fVIII antigen levels were measured by ELISA to determine the specific coagulant activity as described under "Experimental Procedures."
When expressed in 10% fetal bovine serum, the specific coagulant activity of the Arg 484 fVIII, respectively). However, when expressed in serum-free medium, the specific activity of the Arg 489 3 Ala mutant was not significantly lower than human B Ϫ fVIII, whose specific activity was unchanged when expressed in serum-free medium. The specific activity of the Tyr 487 3 Ala mutant was 72% of human B Ϫ fVIII, which, although statistically significant, represents a minor reduction in specific activity. The reduction in specific activity of the Tyr 487 3 Ala and Arg 489 3 Ala mutants may represent proteolysis due to components in fetal bovine serum, which is not observed with human B Ϫ fVIII or the other mutants.
Inhibition of fVIII Alanine Mutants by Murine Monoclonal A2 Inhibitor, mAb413-Previous studies have shown that mAb413 binds to a similar or the same epitope as human A2 inhibitors (6) . The inhibition of the fVIII mutants by mAb413 was measured using the Bethesda assay and compared with human B Ϫ fVIII (Fig. 2) . ؊ fVIII and alanine scanning mutagenesis region. The numbers above the domain structure refer to thrombin cleavage sites, using the sequence of full-length human fVIII as reference (19) . The filled area corresponds to an acidic polypeptide cleavage fragment corresponding to human fVIII residues Glu 1649 -Arg 1689 . The stippled region corresponds to the major A2 epitope determinant defined by Arg 484 -Ile 508 (17) . The boxed areas correspond to the nine differences between human and porcine fVIII in this region. These sites were individually mutated to alanine in human B Ϫ fVIII in this study.
CHA, JM, NS, RC, and WD ( (17) . Fig. 3 shows that inhibition of HP9 by all the plasmas except WD was reduced by greater than 90%. The inhibition by WD of HP9 was 75% of human B Ϫ fVIII, which is most likely due the presence of inhibitory non-A2 antibodies (see "Experimental Procedures"). All the plasmas inhibited HP13 better than HP9 or HP12, suggesting that the antibodies bind human residues within the Arg 489 -Ile 508 segment, outside the HP13 substitution region (Arg 484 -Ser 488 ). Overall, the data show that A2 binding by the antibodies in the plasmas is directed to the Arg 484 -Ile 508 determinant.
Inhibition of fVIII Alanine Mutants by A2-specific Patient
Inhibitors-The inhibition of the nine alanine mutants by CHA, JM, NS, RC, and WD patient inhibitor plasmas was measured by the Bethesda assay (Fig. 4) Figs. 2 and 4) . In particular, Arg 489 3 Ala, which is the most important energetically in the interaction of fVIII with mAb413, was inhibited relatively well by the patient plasmas.
DISCUSSION
Alanine scanning mutagenesis has been used widely to study binding sites on proteins (25, 26) . Protein-protein interactions are dominated by electrostatic effects, hydrogen bonding, and hydrophobic interactions between large, nonpolar side chains. Alanine is used as a substitute because it is uncharged and has the smallest amino acid side chain except glycine, which is not
FIG. 2. Inhibition of human B
؊ fVIII and fVIII A2 alanine mutants by murine anti-human A2 mAb413. The Bethesda titers for human B Ϫ fVIII and the mutants were measured and compared as described under "Experimental Procedures." The inhibition of human B Ϫ fVIII is defined as 100%. preferred because it can change the main chain conformation of the protein.
Analysis of protein-protein complexes by x-ray crystallography shows that typically 20 -30 amino acid side chains of a protein make contact with its binding partner (27) . Interestingly, alanine scanning mutagenesis studies typically reveal that only a few of these residues contribute significantly to the binding energy (28 -31) . Thus, the structural epitope of a protein, which is defined as the side chains buried at the binding interface, is larger than the functional epitope, which is defined as the side chains that contribute to the binding energy (32) . Additionally, the sum of the changes in binding energy of individual alanine mutants typically exceeds the total binding energy for the interaction of the wild-type protein because of side chain interactions (26) . Therefore, although alanine scanning mutagenesis can be used to identify amino acid side chains that contribute significantly to binding, it is not possible to determine quantitatively the binding energies associated with individual amino acid side chains.
Although the structural epitope for fVIII A2 inhibitors has not been determined by x-ray crystallography, homolog scanning mutagenesis using recombinant human/porcine hybrid fVIII molecules has located a major determinant for human inhibitors and for mAb413 to residues Arg 484 -Ile 508 (17) . A 3.1-Å x-ray structure is available for ceruloplasmin, which contains three A domains homologous to fVIII (33) . Each ceruloplasmin A domain is composed of two homologous subdomains that form a plastocyanin-type ␤-barrel. Homology models of the fVIII A1, A2, and A3 domains based on the ceruloplasmin and nitrite reductase structures suggest that residues Val 483 -Glu 507 lie in an exposed loop between ␤-sheets bounded by D482 and Ile 508 (34, 35) in close agreement with the region identified by homolog scanning mutagenesis.
In this study, we made nine alanine substitutions within the human Arg 484 -Ile 508 segment where human and porcine fVIII differ. The results with mAb413 are typical of an alanine scanning mutagenesis study. Four of the nine mutants showed greater than 90% decreases in antibody inhibition in the Bethesda assay, and the remainder showed only mild decreases in antibody inhibition (Fig. 2) . Arg 489 appears to be the most important residue that contributes to inhibition by mAb413, since the inhibition of the Arg 489 3 Ala mutant was reduced by over 10-fold compared with the other mutants.
Several findings have indicated that mAb413 and patient A2 inhibitors bind to the same structural region in fVIII. mAb413 competes with human A2 inhibitors for binding to fVIII (6) . Both inhibit fVIIIa in the intrinsic pathway factor X activation complex by a noncompetitive mechanism (36) . Patient A2 inhibitors and mAb413 are poor inhibitors of HP9, which contains substitution of the human Arg 484 -Ile 508 by the homologous porcine segment (17) . However, the pattern of inhibition of the patient antibodies toward the alanine mutants is different from mAb413 (Figs. 2 and 4) X-ray structural analysis shows that, whereas D1.3 binds lysozyme and anti-D1.3 using essentially the same set of combining site residues, the functionally important residues of D1.3 are different for the two interactions.
Another difference between patient antibodies and mAb413 is that patient antibodies inhibit mutants more effectively than mAb413 does. The polyclonal nature of the patient antibodies may account for this behavior. Most likely, A2 antibodies in a given plasma are a population of high affinity antibodies that compete for binding to fVIII because they recognize different functional epitopes within a structural epitope. Single alanine substitutions could greatly reduce the inhibition by a given monoclonal antibody within this population with little change in the inhibition by the entire population. Alternatively, residues within the region bounded by Arg 484 -Ile 508 that are identical in human and porcine fVIII may contribute significantly to antibody binding. These residues were not mutated in this study. This hypothesis must be considered together with the finding that insertion of the porcine Arg 484 -Ile 508 sequence into human B Ϫ fVIII decreases the Bethesda titer by greater than 90% in four of the five patient antibodies tested (Fig. 3) . It is possible that some porcine replacements do not remove a favorable interaction between antibody and a human residue but instead substitute a residue that is highly unfavorable for antibody binding. 508 3 Ala by human inhibitor plasmas JM, RC, NS, WD, and CHA. fVIII inhibition was determined as described in Fig. 2. testing of A2 monoclonal antibodies isolated from the human A2 inhibitor population.
Alanine substitutions at critical positions produce novel recombinant fVIII molecules that retain procoagulant function and have reduced inhibition by A2 antibodies. Extension of this approach to other fVIII epitopes could lead to the design of a recombinant fVIII molecule that is useful in the treatment of inhibitor patients. However, the reduction in antigenicity toward patient A2 inhibitors achieved by single alanine substitutions is less than that seen with hybrid human/porcine fVIII molecules. Multiple alanine substitutions at inhibitor epitopes may further reduce antigenicity. Alternatively, replacement of the common inhibitor epitopes with porcine sequences may be superior to alanine mutagenesis for therapeutic purposes.
A more general problem is to decrease immunogenicity of fVIII, i.e. to decrease the occurrence of clinically significant inhibitors, in hemophilia A patients who are undergoing fVIII replacement therapy. The regulation of the immune response to fVIII is poorly understood. In particular, it is not clear why only two or three epitopes dominate the fVIII inhibitor response. Structural studies indicate that the entire surface of a protein is immunogenic, at least with selected experimental protein antigens under certain conditions of antigenic stimulus, such as the use of adjuvants (28, 37, 38) . An epitope could be immunodominant, by virtue of the concentration or affinity of its cognate antibodies, because of T cell regulation of antibody producing B cells and be independent of the structure of the epitope. Alternatively, the structure of the epitope could contribute intrinsically to immunodominance. In the latter instance, amino acid side chains within the epitope would partly determine the degree to which the immune system can make high affinity antibodies.
All of the patient antibodies in this study appear to recognize a similar epitope (Fig. 4) . The consistent pattern of antibody recognition at the amino acid level is remarkable, especially considering that the antibodies come from patients in two very different immunological settings (i.e. alloimmune and autoimmune, Table I ). If the A2 epitope is intrinsically immunogenic, then it is possible that mutagenesis of immunodominant residues could yield a less immunogenic fVIII molecule.
